{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:34Z","timestamp":1790710954948,"version":"4.1.0"},"reference-count":155,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Epilepsy is a widely diffused neurological disorder including a heterogeneous range of syndromes with different aetiology, severity and prognosis. Pharmacological treatments are based on the use, either in mono- or in polytherapy, of antiseizure medications (ASMs), which act at different synaptic levels, generally modifying the excitatory and\/or inhibitory response through different action mechanisms. To reduce the risk of adverse effects and drug interactions, ASMs levels should be closely evaluated in biological fluids performing an appropriate Therapeutic Drug Monitoring (TDM). However, many decisions in TDM are based on the determination of the total drug concentration although measurement of the free fraction, which is not bound to plasma proteins, is becoming of ever-increasing importance since it correlates better with pharmacological and toxicological effects. Aim of this work has been to review methodological aspects concerning the evaluation of the free plasmatic fraction of some ASMs, focusing on the effect and the clinical significance that drug-protein binding has in the case of widely used drugs such as valproic acid, phenytoin, perampanel and carbamazepine. Although several validated methodologies are currently available which are effective in separating and quantifying the different forms of a drug, prospective validation studies are undoubtedly needed to better correlate, in real-world clinical contexts, pharmacokinetic monitoring to clinical outcomes.<\/jats:p>","DOI":"10.3390\/pharmaceutics13081208","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:35:32Z","timestamp":1628156132000},"page":"1208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-3220","authenticated-orcid":false,"given":"Bruno","family":"Charlier","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Coglianese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-4032","authenticated-orcid":false,"given":"Federica","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-0372","authenticated-orcid":false,"given":"Ugo","family":"de Grazia","sequence":"additional","affiliation":[{"name":"Laboratory of Neurological Biochemistry and Neuropharmacology, Fondazione IRCCS \u201cIstituto Neurologico Carlo Besta\u201d, 20133 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Felicia","family":"Operto","sequence":"additional","affiliation":[{"name":"Operative Unit of Child Neuropsychiatry, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-0081","authenticated-orcid":false,"given":"Giangennaro","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Child Neuropsychiatry, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-9118","authenticated-orcid":false,"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-5018","authenticated-orcid":false,"given":"Fabrizio","family":"Dal Piaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-7569","authenticated-orcid":false,"given":"Viviana","family":"Izzo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"},{"name":"Operative Unit of Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.anpedi.2019.09.008","article-title":"Nuevos f\u00e0rmacos antiepil\u00e9pticos en Pediatr\u00eca","volume":"91","year":"2019","journal-title":"An. Pediatr."},{"key":"ref_2","first-page":"36","article-title":"Childhood epilepsy: An update on diagnosis and management","volume":"5","author":"Saad","year":"2014","journal-title":"Am. J. Neurosc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ensci.2016.06.003","article-title":"Antiepileptic drugs in development pipeline: A recent update","volume":"4","author":"Kaur","year":"2016","journal-title":"eNeurologicalSci"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejpn.2013.02.003","article-title":"Advancing the management of childhood epilepsies","volume":"17","author":"Cross","year":"2013","journal-title":"Eur. J. Pediatr. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1535759720905516","article-title":"Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines","volume":"20","author":"French","year":"2020","journal-title":"Epilepsy Curr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2019.07.006","article-title":"Action of antiepileptic drugs on neurons","volume":"42","author":"Kobayashi","year":"2019","journal-title":"Brain Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_9","first-page":"508","article-title":"Update on Antiepileptic Drugs 2019","volume":"25","year":"2019","journal-title":"Continuum"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dolphin, A.C. (2012). Calcium channel \u03b1 \u2082 \u03b4 subunits in epilepsy and as targets for antiepileptic drugs, Jasper\u2019s Basic Mechanisms of the Epilepsies.","DOI":"10.1093\/med\/9780199746545.003.0075"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s40265-015-0465-z","article-title":"Perampanel: A Review in Drug-Resistant Epilepsy","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neulet.2012.03.056","article-title":"Levetiracetam inhibits neurotransmitter release associated with CICR","volume":"518","author":"Fukuyama","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1684\/epd.2014.0704","article-title":"The clinical pharmacology of traditional antiepileptic drugs","volume":"16","author":"Vajda","year":"2014","journal-title":"Epileptic. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13181-017-0626-4","article-title":"The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs","volume":"13","author":"LaPenna","year":"2017","journal-title":"J. Med. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cca.2014.06.002","article-title":"Advances in anti-epileptic drug testing","volume":"436","author":"Krasowski","year":"2014","journal-title":"Clin. Chim. Acta."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1373\/jalm.2017.023689","article-title":"Clinical Use and Monitoring of Antiepileptic Drugs","volume":"3","author":"Knezevic","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.9740\/mhc.2015.01.008","article-title":"Pharmacokinetic characteristics of antiepileptic drugs (AEDs)","volume":"6","author":"Marvanova","year":"2016","journal-title":"Ment. Health Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs R D"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13054-018-2066-1","article-title":"Antiepileptic drugs in critically ill patients","volume":"22","author":"Farrokh","year":"2018","journal-title":"Crit. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14740338.2016.1225721","article-title":"Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry","volume":"15","author":"Gerlach","year":"2016","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40272-018-0302-4","article-title":"Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents","volume":"20","author":"Iapadre","year":"2018","journal-title":"Paediatr. Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"L\u00f6scher, W., and Friedman, A. (2020). Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020591"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.2174\/138161211797440212","article-title":"Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected","volume":"17","author":"Fedrowitz","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/phar.1965","article-title":"Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia","volume":"37","author":"Frenette","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel Serum Concentrations in Adults with Epilepsy: Effect of Dose, Age, Sex and Concomitant Anti-Epileptic Drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/epi.14446","article-title":"Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy","volume":"59","author":"Contin","year":"2018","journal-title":"Epilepsia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14656566.2016.1161026","article-title":"Stiripentol and Vigabatrin current roles in the treatment of epilepsy","volume":"17","author":"Chiron","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425255.2016.1145657","article-title":"Pharmacological considerations in the use of stiripentol for the treatment of epilepsy","volume":"12","author":"Verrotti","year":"2016","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2515\/therapie\/2012014","article-title":"Therapeutic drug monitoring of stiripentol","volume":"67","author":"Verdier","year":"2012","journal-title":"Therapie"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","article-title":"Concentrations of stiripentol in children and adults with epilepsy: The influence of dose, age, and comedication","volume":"34","author":"May","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.4155\/bio.11.187","article-title":"Monitoring free drug concentrations: Challenges","volume":"3","author":"Musteata","year":"2011","journal-title":"Bioanalysis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4155\/bio-2017-0053","article-title":"Measuring and using free drug concentrations: Has there been \u2018real\u2019 progress?","volume":"9","author":"Musteata","year":"2017","journal-title":"Bioanalysis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.drudis.2014.11.010","article-title":"Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: Lack of harmonisation and guidelines","volume":"20","author":"Illamola","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dasgupta, A., and Krasowski, M. (2019). Therapeutic Drug Monitoring Data: A Concise Guide, Academic Press. [4th ed.].","DOI":"10.1016\/B978-0-12-815849-4.00001-3"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106947","DOI":"10.1016\/j.yebeh.2020.106947","article-title":"Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: A cross-sectional study","volume":"105","author":"Kumar","year":"2020","journal-title":"Epilepsy Behav."},{"key":"ref_42","unstructured":"Ghosh, S. (2019). Digoxin and Other Cardiac Glycosides. Principles and Practice of Critical Care Toxicology, Jaypee Brothers Medical Pub."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.21536","article-title":"Validation of a free phenytoin assay on Cobas c501 analyzer using calibrators from Cobas Integra free phenytoin assay by comparing its performance with fluorescence polarization immunoassay for free phenytoin on the TDx analyzer","volume":"27","author":"Dasgupta","year":"2013","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1309\/LMFCR2FWS1IMV4GX","article-title":"An automated real-time free phenytoin assay to replace the obsolete Abbott TDx method","volume":"45","author":"Williams","year":"2014","journal-title":"Lab. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1515\/cclm-2014-0472","article-title":"Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots","volume":"53","author":"Baldelli","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Garz\u00f3n, V., Pinacho, D.G., Bustos, R.H., Garz\u00f3n, G., and Bustamante, S. (2019). Optical Biosensors for Therapeutic Drug Monitoring. Biosensors, 9.","DOI":"10.3390\/bios9040132"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e3950","DOI":"10.1002\/bmc.3950","article-title":"Development and validation of a reversed-phase HPLC method for licarbazepine monitoring in serum of patients under oxcarbazepine treatment","volume":"31","author":"Begas","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jssc.201801108","article-title":"HPLC determination of \u03b3-aminobutyric acid and its analogs in human serum using precolumn fluorescence labeling with 4-(carbazole-9-yl)-benzyl chloroformate","volume":"42","author":"Yu","year":"2019","journal-title":"J. Sep. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.4155\/bio-2016-0211","article-title":"Sensitive inexpensive HPLC determination of four antiepileptic drugs in human plasma: Application to PK studies","volume":"8","author":"Ibrahim","year":"2016","journal-title":"Bioanalysis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/bmc.3004","article-title":"Chiral chromatographic resolution of antiepileptic drugs and their metabolites: A challenge from the optimization to the application","volume":"28","author":"Fortuna","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/FTD.0000000000000516","article-title":"Development and Validation of an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for the Concurrent Measurement of Gabapentin, Lamotrigine, Levetiracetam, Monohydroxy Derivative of Oxcarbazepine, and Zonisamide Concentrations in Serum in a Clinical Setting","volume":"40","author":"Palte","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sommerfeld-Klatta, K., Zieli\u0144ska-Psuja, B., Kara\u017aniewcz-\u0141ada, M., and G\u0142\u00f3wka, F.K. (2020). New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs). Molecules, 25.","DOI":"10.3390\/molecules25215083"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","volume":"26","author":"Shibata","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jat\/bku070","article-title":"Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases","volume":"38","author":"Deeb","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/dta.1733","article-title":"Determination of a selection of anti-epileptic drugs and two active metabolites in whole blood by reversed phase UPLC-MS\/MS and some examples of application of the method in forensic toxicology cases","volume":"7","author":"Karinen","year":"2015","journal-title":"Drug Test Anal."},{"key":"ref_56","first-page":"183","article-title":"Correlation between measured and calculated free phenytoin serum concentration in neurointensive care patients with hypoalbuminemia","volume":"13","author":"Javadi","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11096-015-0241-x","article-title":"Free phenytoin assessment in patients: Measured versus calculated blood serum levels","volume":"38","author":"Tobler","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.xphs.2020.12.001","article-title":"Method for Simultaneous Determination of Free Concentration, Total Concentration, and Plasma Binding Capacity in Clinical Samples","volume":"110","author":"Cibotaru","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"113475","DOI":"10.1016\/j.ab.2019.113475","article-title":"Determination of unbound valproic acid in plasma using centrifugal ultrafiltration and gas chromatography: Application in TDM","volume":"588","author":"Gu","year":"2020","journal-title":"Anal. Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1038\/s41598-020-69102-y","article-title":"Comparing ultrafiltration and equilibrium dialysis to measure unbound plasma dolutegravir concentrations based on a design of experiment approach","volume":"10","author":"Metsu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.4155\/bio.13.274","article-title":"The bioanalytical challenge of determining unbound concentration and protein binding for drugs","volume":"5","author":"Nilsson","year":"2013","journal-title":"Bioanalysis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.xphs.2018.10.004","article-title":"Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS\/MS Detection","volume":"108","author":"Isbell","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2012.11.018","article-title":"A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds","volume":"75","author":"Wang","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejps.2012.11.006","article-title":"Effect of volume ratio of ultrafiltrate to sample solution on the analysis of free drug and measurement of free carbamazepine in clinical drug monitoring","volume":"48","author":"Dong","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Toma, C.M., Imre, S., Vari, C.E., Muntean, D.L., and Tero-Vescan, A. (2021). Ultrafiltration Method for Plasma Protein Binding Studies and Its Limitations. Processes, 9.","DOI":"10.3390\/pr9020382"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jchromb.2015.07.048","article-title":"Pretreatment of plasma samples by a novel hollow fiber centrifugal ultrafiltration technique for the determination of plasma protein binding of three coumarins using acetone as protein binding releasing agent","volume":"1001","author":"Li","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.chroma.2013.09.078","article-title":"Accuracy assessment on the analysis of unbound drug in plasma by comparing traditional centrifugal ultrafiltration with hollow fiber centrifugal ultrafiltration and application in pharmacokinetic study","volume":"1318","author":"Zhang","year":"2013","journal-title":"J. Chromatogr. A"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/FTD.0000000000000225","article-title":"The Influence of Plasma Albumin Concentration on the Analysis Methodology of Free Valproic Acid by Ultrafiltration and Its Application to Therapeutic Drug Monitoring","volume":"37","author":"Zhang","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"28048","DOI":"10.1039\/C7RA02991H","article-title":"The significance of a new parameter\u2013Plasma protein binding\u2013In therapeutic drug monitoring and its application to carbamazepine in epileptic patients","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0000000000000431","article-title":"Development of a Simple and Rapid Method to Measure Free Fraction of Valproic Acid in Plasma Using Ultrafiltration and Ultra High Performance Liquid Chromatography-Mass Spectroscopy: Application to Therapeutic Drug Monitoring","volume":"39","author":"Xu","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.03.011","article-title":"In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review","volume":"86","author":"Lambrinidis","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jpba.2015.08.002","article-title":"Sensitive determination of plasma protein binding of cationic drugs using mixed-mode solid-phase microextraction","volume":"115","author":"Peltenburg","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6947-12-7","article-title":"Clinical decision support of therapeutic drug monitoring of phenytoin: Measured versus adjusted phenytoin plasma concentrations","volume":"12","author":"Krasowski","year":"2012","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1060028016628166","article-title":"A Comprehensive Review on the Predictive Performance of the Sheiner-Tozer and Derivative Equations for the Correction of Phenytoin Concentrations","volume":"50","author":"Kiang","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"ref_76","first-page":"1","article-title":"Therapeutic drug monitoring of carbamazepine","volume":"4","author":"Panday","year":"2017","journal-title":"Int. J. Neurorehabil."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-017-0553-1","article-title":"Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial","volume":"57","author":"Georgoff","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.seizure.2018.04.012","article-title":"Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy","volume":"59","author":"Nasreddine","year":"2018","journal-title":"Seizure"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009734.2011.640412","article-title":"Apparent clearance of valproic acid in elderly epileptic patients: Estimation of the confounding effect of albumin concentration","volume":"117","author":"Lampon","year":"2012","journal-title":"Ups. J. Med. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Tseng, Y.J., Huang, S.Y., Kuo, C.H., Wang, C.Y., Wang, K.C., and Wu, C.C. (2020). Safety range of free valproic acid serum concentration in adult patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238201"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/phar.1912","article-title":"Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review","volume":"37","author":"Riker","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpba.2014.04.009","article-title":"The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection","volume":"97","author":"Kotani","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1176\/appi.ajp.2016.16030326","article-title":"Ibuprofen May Increase Pharmacological Action of Valproate by Displacing It From Plasma Proteins: A Case Report","volume":"173","author":"Lana","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0310057X1304100505","article-title":"Phenytoin loading doses in adult critical care patients: Does current practice achieve adequate drug levels?","volume":"41","author":"Putt","year":"2013","journal-title":"Anaesth. Intensive Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3349\/ymj.2009.50.4.517","article-title":"Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients","volume":"50","author":"Hong","year":"2009","journal-title":"Yonsei Med. J."},{"key":"ref_88","unstructured":"Melmon, K.E., and Morrelli, H.F. (1978). Clinical Pharmacokinetics: The Use of Plasma Concentrations of Drugs. Clinical Pharmacology: Basic Principles in Therapeutics, Macmillan."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40268-020-00323-2","article-title":"Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling","volume":"20","author":"Jun","year":"2020","journal-title":"Drugs R D"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/FTD.0000000000000739","article-title":"A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients","volume":"42","author":"Barra","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_91","unstructured":"Fycompa (2013). Product Monograph, Eisai Limited."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.2013.754883","article-title":"Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures","volume":"14","author":"Rektor","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_93","unstructured":"European Medicines Agency EMA (2021, April 13). Fycompa SPC Perampanel (Fycompa). Summary of Product Characteristics., Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/002434\/WC500130815.pdf."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eplepsyres.2015.03.005","article-title":"Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies","volume":"113","author":"Laurenza","year":"2015","journal-title":"Epilepsy Res."},{"key":"ref_95","unstructured":"US Food and Drug Administration FDA (2021, March 23). Clinical Pharmacology Review. Reference ID: 3205587, Available online: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM332052.pdf."},{"key":"ref_96","first-page":"S81","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Zare","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_97","unstructured":"Al Khalili, Y., Sekhon, S., and Jain, S. (2021). Carbamazepine Toxicity, Stat Pearls Publishing."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40272-020-00428-w","article-title":"Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children","volume":"23","author":"Holmes","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-197803010-00003","article-title":"Therapeutic drug monitoring in saliva","volume":"3","author":"Danhof","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007691-198208000-00001","article-title":"The use of saliva in therapeutic drug monitoring","volume":"4","author":"Mucklow","year":"1982","journal-title":"Ther. Drug Monit."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-199223050-00003","article-title":"Therapeutic drug monitoring in saliva. An update","volume":"23","author":"Drobitch","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","article-title":"Therapeutic drug concentration monitoring using saliva samples: Focus on anticonvulsants","volume":"36","author":"Liu","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0897190007305139","article-title":"Salivary monitoring of antiepileptic drugs","volume":"20","author":"Baumann","year":"2007","journal-title":"J. Pharm. Pract."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"ref_105","first-page":"237","article-title":"Therapeutic Monitoring of Anticonvulsants: Use of Saliva as Biological Fluid","volume":"12","author":"Fagiolino","year":"2016","journal-title":"Epileptology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1152\/ajplegacy.1954.178.1.155","article-title":"Excretion of Na, K, Cl, CO2 in human parotid saliva","volume":"178","author":"Thaysen","year":"1954","journal-title":"Am. J. Physiol."},{"key":"ref_107","first-page":"83","article-title":"Saliva-plasma drug concentration ratios during absorption: Theoretical considerations and pharmacokinetic implications","volume":"57","author":"Posti","year":"1982","journal-title":"Pharm. Acta Helv."},{"key":"ref_108","first-page":"653","article-title":"Reasons for intraindividual inconstancy of the digoxin saliva to serum concentration ratio","volume":"27","author":"Haeckel","year":"1989","journal-title":"J. Clin. Chem. Clin. Biochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00007691-199009000-00009","article-title":"Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic children","volume":"12","author":"Siegel","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"110330","DOI":"10.1016\/j.forsciint.2020.110330","article-title":"A new LC-MS\/MS confirmation method for the determination of 17 drugs of abuse in oral fluid and its application to real samples","volume":"312","author":"Bassotti","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FTD.0000000000000600","article-title":"LC-MS\/MS-Based Quantification of 9 Antiepileptic Drugs from a Dried Sample Spot Device","volume":"41","author":"Cangemi","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00216-019-01654-z","article-title":"Determination of methadone and EDDP in oral fluid using the dried saliva spots sampling approach and gas chromatography-tandem mass spectrometry","volume":"411","author":"Ribeiro","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1007\/s00216-019-02005-8","article-title":"Determination of antipsychotic drugs in oral fluid using dried saliva spots by gas chromatography-tandem mass spectrometry","volume":"411","author":"Caramelo","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.aca.2016.05.057","article-title":"Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS\/MS detection","volume":"934","author":"Zheng","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jat\/bky064","article-title":"Determination of Antiepileptic Drugs Using Dried Saliva Spots","volume":"43","author":"Carvalho","year":"2019","journal-title":"J. Anal. Toxicol."},{"key":"ref_116","first-page":"27","article-title":"Comparative study of the levels of anticonvulsants and their free fractions in venous blood, saliva and capillary blood in man","volume":"15","year":"1984","journal-title":"J. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.1982.tb01431.x","article-title":"Saliva carbamazepine levels in children before and during multiple dosing","volume":"13","author":"Moreland","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-198403000-00008","article-title":"The place of saliva in antiepileptic drug monitoring","volume":"6","author":"Knott","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1469-8749.1986.tb03922.x","article-title":"A study on carbamazepine levels, including estimation of 10-11 epoxy-carbamazepine and levels in free plasma and saliva","volume":"28","author":"Tomlin","year":"1986","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/088307389000500219","article-title":"Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slowrelease formulations","volume":"5","author":"Nilsson","year":"1990","journal-title":"J. Child Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00007691-199009000-00016","article-title":"Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin in saliva","volume":"12","author":"Miles","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00007691-199712000-00006","article-title":"Is saliva suitable for therapeutic monitoring of anticonvulsants in children: An evaluation in the routine clinical setting","volume":"19","author":"Gorodischer","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.27.5.409","article-title":"Salivary levels of anticonvulsants: A practical approach to drug monitoring","volume":"27","author":"McAuliffe","year":"1977","journal-title":"Neurology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00007691-198102000-00006","article-title":"Salivary anticonvulsant levels in children: A comparison of methods","volume":"3","author":"Goldsmith","year":"1981","journal-title":"Ther. Drug Monit."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(77)92098-0","article-title":"Salivary carbamazepine concentrations","volume":"1","author":"Chambers","year":"1977","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00443121","article-title":"Use of saliva in monitoring carbamazepine medication in epileptic children","volume":"126","author":"Bartels","year":"1977","journal-title":"Eur. J. Pediat."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cpt1978233320","article-title":"Kinetics of carbamazepine and carbamazepine\u2013epoxide, determined by use of plasma and saliva","volume":"23","author":"Westenberg","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.1980.223","article-title":"Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum","volume":"28","author":"Paxton","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0404.1980.tb01503.x","article-title":"Value of saliva samples in monitoring carbamazepine concentrations in epileptic patients","volume":"61","author":"Kristensen","year":"1980","journal-title":"Acta Neurol. Scand."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.1981.tb01851.x","article-title":"Salivary concentration and plasma protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients","volume":"12","author":"MacKichan","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/adc.56.8.637","article-title":"Saliva carbamazepine and phenytoin level monitoring","volume":"56","author":"Rylance","year":"1981","journal-title":"Arch. Dis. Child."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00007691-199103000-00013","article-title":"Interindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva","volume":"13","author":"Miles","year":"1991","journal-title":"Ther. Drug Monit."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2125.1993.tb05700.x","article-title":"A simple collection method for saliva in children: Potential for home monitoring of carbamazepine therapy","volume":"35","author":"Chee","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1157.1995.tb01668.x","article-title":"Use of saliva in home monitoring of carbamazepine levels","volume":"36","author":"Rosenthal","year":"1995","journal-title":"Epilepsia"},{"key":"ref_135","first-page":"60","article-title":"Correlation of serum and salivary carbamazepine concentration in epileptic patients: Implications for therapeutic drug monitoring","volume":"50","author":"Vasudev","year":"2002","journal-title":"Neurol. India"},{"key":"ref_136","first-page":"19","article-title":"Salivary free concentrations of antiepileptic drugs: An evaluation in routine clinical setting","volume":"103","author":"Deleu","year":"2003","journal-title":"Acta Neurol. Belg."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1528-1157.1975.tb04758.x","article-title":"Diphenylhydantoin, phenobarbital and primidone in saliva, plasma, and cerebrospinal fluid","volume":"16","author":"Schmidt","year":"1975","journal-title":"Epilepsia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2125.1984.tb05015.x","article-title":"Effect of valproate on free plasma phenytoin concentrations","volume":"18","author":"Tsanaclis","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpt1975186742","article-title":"Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay","volume":"18","author":"Cook","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt1978245563","article-title":"Drug concentration in saliva","volume":"24","author":"Mucklow","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3476(81)80786-X","article-title":"Saliva phenobarbital and phenytoin concentrations in epileptic adolescents","volume":"98","author":"Friedman","year":"1981","journal-title":"J. Pediatr."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(76)92404-1","article-title":"Salivary phenytoin concentrations in epilepsy and in chronic renal failure","volume":"2","author":"Reynolds","year":"1976","journal-title":"Lancet"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00007691-198309000-00014","article-title":"Monitoring phenytoin salivary and plasma utrafiltrates of pediatric patients","volume":"5","author":"Bachmann","year":"1983","journal-title":"Ther. Drug Monit."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1471-0528.1986.tb07827.x","article-title":"Phenytoin kinetics during pregnancy and the puerperium","volume":"93","author":"Knott","year":"1986","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00007691-199007000-00006","article-title":"Monitoring phenytoin therapy using citric acid-stimulated saliva in infants and children","volume":"12","author":"Lifshitz","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"ref_146","first-page":"172","article-title":"Correlation between serum and salivary phenytoin concentrations in Thai epileptic children","volume":"94","author":"Liamsuwan","year":"2011","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00196118","article-title":"Effect of saliva flow rate on saliva phenytoin concentrations: Implications for therapeutic monitoring","volume":"46","author":"Kamali","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000457481","article-title":"Salivary excretion of drugs in children: Theoretical and practical issues in therapeutic drug monitoring","volume":"19","author":"Gorodischer","year":"1992","journal-title":"Dev. Pharmacol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0378-4347(00)80396-5","article-title":"Valproic acid analysis in saliva and serum using selected monitoring (electron ionization) of the tert-butyldimethylsilyl derivatives","volume":"227","author":"Abbott","year":"1982","journal-title":"J. Chromatogr."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-3476(82)80490-3","article-title":"Saliva and serum valproic acid levels in epileptic children","volume":"100","author":"Fung","year":"1982","journal-title":"J. Pediatr."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","article-title":"The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers","volume":"23","author":"Nitsche","year":"1982","journal-title":"Epilepsia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.16513","article-title":"Usefulness of saliva for perampanel therapeutic drug monitoring","volume":"61","author":"Kim","year":"2020","journal-title":"Epilepsia"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/17425255.2020.1801633","article-title":"Albumin-based drug designs for pharmacokinetic modulation","volume":"16","author":"Pilati","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_154","first-page":"32","article-title":"Novel Drug Targets for the Treatment of Cardiac Diseases","volume":"15","author":"Pingeon","year":"2017","journal-title":"Curr. Pharm. Person. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/8\/1208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:41:00Z","timestamp":1760164860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/8\/1208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":155,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["pharmaceutics13081208"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13081208","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}